Coronavirus disease 2019 (COVID‐19) as a potential trigger for benign recurrent intrahepatic cholestasis

Çalhan, Turan; Yivli, Elif

doi:10.1002/ccr3.5557

Cited by 2 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LPS can induce pro-inflammatory cytokine production from Kupffer cells, leading to the downregulation of canalicular bile salt transporters and predisposing individuals to intrahepatic cholestasis [33]. Viral diseases, including influenza and SARS-CoV-2 infections, have also been associated with BRIC attacks [33,44].…”

Section: Triggering Factors For Bricmentioning

confidence: 99%

“…Combination therapies, such as cholestyramine (4 g daily) with UDCA (15-20 g daily) and rifampicin, have been explored in non-responsive BRIC cases [15,18,19,24,44,60]. Endoscopic nasobiliary drainage is a well-established method of biliary decompression where the distal end of the drain is placed in the common bile duct and the proximal end emerges out through the nose.…”

Section: Treatment Options and Future Challenges In Bricmentioning

confidence: 99%

See 1 more Smart Citation

Benign Recurrent Intrahepatic Cholestasis: Where Are We Now?

Geladari,

Vallianou,

Margellou

et al. 2024

Gastroenterology Insights

View full text Add to dashboard Cite

Benign recurrent intrahepatic cholestasis (BRIC) stands as a rare genetic contributor to cholestasis, aligning itself within the spectrum of inherited intrahepatic cholestasis syndromes, such as progressive familial intrahepatic cholestasis (PFIC) and intrahepatic cholestasis of pregnancy. Manifesting in infancy or early adulthood, BRIC is marked by recurrent episodes of jaundice accompanied by intense pruritus, enduring from weeks to years across the lifespan. Normal gamma-glutamyl transferase (GGT) levels are a characteristic laboratory finding. Initially considered unlikely to progress to chronic liver disease or cirrhosis, some reports suggest BRIC may evolve into a continuous and progressive form of cholestasis. Moreover, these recurrent cholestatic episodes significantly impact quality of life, and certain mutations elevate the risk of hepatobiliary malignancy. Between episodes, histological findings of centrilobular cholestasis and abnormal laboratory parameters revert to normal, potentially obviating the need for liver biopsy. This review focuses on the genetic aspects of BRIC, its pathophysiology, clinical presentation, and prognosis. Additionally, it outlines triggering factors and available treatment options.

show abstract

Section: Triggering Factors For Bricmentioning

confidence: 99%

Section: Treatment Options and Future Challenges In Bricmentioning

confidence: 99%

Benign Recurrent Intrahepatic Cholestasis: Where Are We Now?

Geladari,

Vallianou,

Margellou

et al. 2024

Gastroenterology Insights

View full text Add to dashboard Cite

show abstract

“…LPS can induce pro-inflammatory cytokine production from Kupffer cells, leading to the downregulation of canalicular bile salt transporters and predisposing individuals to intrahepatic cholestasis [27]. Viral diseases, including influenza and SARS-CoV-2 infections, have also been associated with BRIC attacks [27,38].…”

Section: Triggering Factors For Bricmentioning

confidence: 99%

“…Combination therapies, such as cholestyramine (4g daily) with UDCA (15-20 g daily) and or rimfampicin have been explored in non-responsive BRIC cases [13,15,18,19,38,55]. Nasobiliary drainage [60,[61][62][63] and, rarely, hemodialysis with specific filters have been attempted with encouraging outcomes in certain cases [56,[64][65].…”

Section: Treatment Options and Future Challenges In Bricmentioning

confidence: 99%

Benign Recurrent Intrahepatic Cholestasis: Where are we now?

Geladari,

Vallianou,

Margellou

et al. 2023

Preprint

View full text Add to dashboard Cite

Benign recurrent intrahepatic cholestasis (BRIC) is a rare genetic cause of cholestasis. It is considered as part of inherited intrahepatic cholestasis syndromes, such as progressive familial intrahepatic cholestasis (PFIC), and intrahepatic cholestasis of pregnancy. BRIC is presented in infancy or in early adulthood. It is characterized by exacerbations and remissions of jaundice with accompanying intense itching, lasting from weeks to years throughout lifetime. Normal gamma-glutamyl transferase (GGT) is a characteristic laboratory finding. Contrary to PFIC, which may progress to cirrhosis, BRIC does not progress to chronic liver disease or cirrhosis. However, incessant episodes of cholestasis result in marked reduction in quality of life and distinct mutations increase the risk of hepatobiliary malignancy. In intervals between the exacerbations, the histological findings of centrilobular cholestasis together with the abnormal laboratory parameters return to normal. In this context, liver biopsy might be avoided. In this review, we will focus on the genetic aspects of BRIC, its pathophysiology, clinical presentation, and prognosis of this autosomal recessive genetically determined cholestatic disorder. Moreover, triggering factors as well as treatment options will be further elucidated.

show abstract

Coronavirus disease 2019 (COVID‐19) as a potential trigger for benign recurrent intrahepatic cholestasis

Cited by 2 publications

References 26 publications

Benign Recurrent Intrahepatic Cholestasis: Where Are We Now?

Benign Recurrent Intrahepatic Cholestasis: Where Are We Now?

Benign Recurrent Intrahepatic Cholestasis: Where are we now?

Contact Info

Product

Resources

About